Tezepelumab + Tezepelumab

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Eosinophilic Esophagitis

Conditions

Eosinophilic Esophagitis

Trial Timeline

Nov 10, 2022 → Mar 23, 2027

NCT ID

NCT05583227

About Tezepelumab + Tezepelumab

Tezepelumab + Tezepelumab is a phase 3 stage product being developed by AstraZeneca for Eosinophilic Esophagitis. The current trial status is active. This product is registered under clinical trial identifier NCT05583227. Target conditions include Eosinophilic Esophagitis.

What happened to similar drugs?

6 of 16 similar drugs in Eosinophilic Esophagitis were approved

Approved (6) Terminated (2) Active (8)

✅BenralizumabAstraZenecaApproved

✅Benralizumab Prefilled SyringeAstraZenecaApproved

✅DupilumabSanofiApproved

✅Dupilumab + PlaceboSanofiApproved

✅Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]Regeneron PharmaceuticalsApproved

❌Benralizumab + Matching placeboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05583227	Phase 3	Active	Nov 10, 2022	Mar 23, 2027	Eosinophilic Esophagitis

Competing Products

20 competing products in Eosinophilic Esophagitis

See all competitors

Product	Company	Stage	Hype Score
KHK4563 + KHK4563 + KHK4563 + Placebo	Kyowa Kirin	Phase 2	35
benralizumab + benralizumab + Placebo	Kyowa Kirin	Phase 2	35
SHR-1703 + SHR-1703 Placebo	Jiangsu Hengrui Medicine	Phase 2	35
NS-229 + Placebo	Nippon Shinyaku	Phase 2	42
Esomeprazole + Budesonide	AstraZeneca	Phase 2/3	38
Benralizumab	AstraZeneca	Approved	43
Cohort	AstraZeneca	Pre-clinical	26
Benralizumab + Matching placebo	AstraZeneca	Phase 3	32
Benralizumab	AstraZeneca	Phase 3	44
Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab	AstraZeneca	Phase 3	44
Benralizumab Prefilled Syringe	AstraZeneca	Approved	50
benralizumab	AstraZeneca	Pre-clinical	33
Benralizumab + Placebo	AstraZeneca	Phase 3	44
Benralizumab	AstraZeneca	Phase 3	47
Benralizumab + Placebo	AstraZeneca	Phase 3	32
Tezepelumab + Placebo	AstraZeneca	Phase 2	42
Benralizumab + Placebo	AstraZeneca	Phase 2/3	38
inhaled/swallowed budesonide + viscous/swallowed budesonide	AstraZeneca	Pre-clinical	26
Benralizumab + 129 Xenon	AstraZeneca	Pre-clinical	30
Benralizumab + Placebo	AstraZeneca	Phase 3	40